Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 10 April 2017 | By Michael Mezher
The European Medicines Agency (EMA) has proposed to change the agency's guideline for investigating drug interactions.
The guideline, last updated in 2012, details how drugmakers should conduct interaction studies to evaluate the potential for drug-drug and drug-food interactions.
"Drug-drug interactions are a common problem during drug treatment and give rise to a large number of hospital admissions as a result of medically important, sometimes serious or even fatal adverse events," EMA writes in its current guideline.
The agency also says that studying drug interactions is growing more important as the European population ages, with more patients taking multiple drugs simultaneously.
According to the concept paper, the guideline needs to be updated to add additional study design recommendations and considerations, as well as clarifications on a handful of issues covered by the previous revision related to in vitro and in vivo studies and labelling.
As such, EMA is asking stakeholders, including drugmakers, academia, healthcare professionals and other regulators, to provide input on the concept paper during a three-month public consultation.
Following the public consultation, EMA says it will begin working on draft revisions, taking into account the comments received.
Tags: drug-drug interaction, drug-food interaction
Regulatory Focus newsletters
All the biggest regulatory news and happenings.